ArticleFrontiers in public health2026

Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes: a BRAVO model-based evaluation.

Jiali Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.